A randomized double-blind placebo-controlled Phase 3 study of Debio 1143 in combo w/ platinum-based chemo & standard fractionation intensitymodulated radiotherapy in patients w/ locally advanced HNSCC suitable for definitive chemoradiotherapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Squamous Cell Carcinoma Of The Head And Neck
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Diagnosis in previously untreated LA-SCCHN (stage III, IVA or IVB) suitable for definitive CRT in at least 1 of the following sites: oropharynx, hypopharynx and/or larynx. 2) In oropharyngeal cancer patients, primary tumors must be HPV negative. 3) No hearing loss. 4) Adequate hematologic, renal and hepatic function.

You may not be eligible for this study if the following are true:

  • 1) Primary tumor of nasopharyngeal, paranasal sinuses, nasal or oral cavity, salivary, thyroid or parathyroid gland pathologies, skin or unknown primary site. 2) Metastatic disease. 3) Prior definitive or adjuvant RadioTherapy (RT) and/or radical surgery to the head and neck region which may jeopardize the primary tumor irradiation plan, or any other prior SCCHN systemic treatment, including investigational agents.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.